ISX |
murine hepatocytes (MMH-D3) |
Source: liver; TumourStage: non-transformed; |
Permissive
|
Mus musculus |
GSE100400
...
|
MA0654.1
|
ISX |
B lymphoblastic leukemia |
Treatment: no Genotype: half SA deletion |
Permissive
|
Mus musculus |
GSE98119
...
|
MA0654.1
|
ISX |
activated B-cells |
Treatment: activating 30 hrs and HU treated Genotype: wildtype |
Permissive
Robust
|
Mus musculus |
GSE98119
...
|
MA0654.1
|
ISX |
activated B-cells |
Treatment: activated, 24 hrs Genotype: wildtype |
Permissive
|
Mus musculus |
GSE98119
...
|
MA0654.1
|
ISX |
activated B-cells |
Treatment: activated, 30 hrs, HU untreated Genotype: wildtype |
Permissive
|
Mus musculus |
GSE98119
...
|
MA0654.1
|
ISX |
activated B-cells |
Treatment: activated, 30 hrs, HU treated Genotype: wildtype |
Permissive
|
Mus musculus |
GSE98119
...
|
MA0654.1
|
ISX |
activated B-cells |
Treatment: activated, 30 hrs, HU untreated Genotype: wildtype |
Permissive
|
Mus musculus |
GSE98119
...
|
MA0654.1
|
ISX |
Secondary MEF cells |
Treatment: DOX induction, day1 Genotype: Mbd3f/- cell line |
Permissive
|
Mus musculus |
GSE102517
...
|
MA0654.1
|
ISX |
Secondary MEF cells |
Treatment: DOX induction, day 2 Genotype: Mbd3f/- cell line |
Permissive
|
Mus musculus |
GSE102517
...
|
MA0654.1
|
ISX |
Secondary MEF cells |
Treatment: DOX induction, N2B27 2i\\LIF medium, day3 Genotype: Mbd3f/- cell line |
Permissive
|
Mus musculus |
GSE102517
...
|
MA0654.1
|
ISX |
Secondary MEF cells |
Treatment: DOX induction, N2B27 2i\\LIF medium, day5 Genotype: Mbd3f/- cell line |
Permissive
|
Mus musculus |
GSE102517
...
|
MA0654.1
|
ISX |
Secondary MEF cells |
Treatment: DOX induction, N2B27 2i\\LIF medium, day6 Genotype: Mbd3f/- cell line |
Permissive
|
Mus musculus |
GSE102517
...
|
MA0654.1
|
ISX |
Secondary MEF cells |
Treatment: DOX induction, N2B27 2i\\LIF medium, day7 Genotype: Mbd3f/- cell line |
Permissive
|
Mus musculus |
GSE102517
...
|
MA0654.1
|
ISX |
Secondary MEF cells |
Treatment: DOX induction, N2B27 2i\\LIF medium, day8 Genotype: Mbd3f/- cell line |
Permissive
|
Mus musculus |
GSE102517
...
|
MA0654.1
|
ISX |
V6.5 (embryonic stem cells) |
Genotype: Mbd3f/- cell line |
Permissive
|
Mus musculus |
GSE102517
...
|
MA0654.1
|
ISX |
induced pluripotent stem cells |
Genotype: Mbd3f/- cell line |
Permissive
|
Mus musculus |
GSE102517
...
|
MA0654.1
|
ISX |
V6.5 (embryonic stem cells) |
Cell type: mEsc |
Permissive
|
Mus musculus |
GSE111264
...
|
MA0654.1
|
ISX |
V6.5 (embryonic stem cells) |
Treatment: DMSO for 24 hrs Cell type: mESC |
Permissive
|
Mus musculus |
GSE111264
...
|
MA0654.1
|
ISX |
V6.5 (embryonic stem cells) |
Treatment: 3 uM I-BRD9 for 24 hours Cell type: mESC |
Permissive
|
Mus musculus |
GSE111264
...
|
MA0654.1
|
ISX |
V6.5 (embryonic stem cells) |
Cell type: mESC |
Permissive
|
Mus musculus |
GSE111264
...
|
MA0654.1
|
ISX |
MLL-AF9 Leukemic Cells |
Genotype: wildtype Strain: C57BL/6 Treatment: Ethanol |
Permissive
Robust
|
Mus musculus |
GSE120063
...
|
MA0654.1
|
ISX |
MLL-AF9 Leukemic Cells |
Genotype: C1B knockout Strain: C57BL/6 Treatment: treated with 10-7M B-estradiol daily for two days (48 hours) |
Permissive
Robust
|
Mus musculus |
GSE120063
...
|
MA0654.1
|
ISX |
primary T-cells |
Strain: C57BL/6 Cell type: Th17 cells |
Permissive
|
Mus musculus |
GSE92531
...
|
MA0654.1
|
ISX |
activated B-cells |
Strain: C57BL/6; |
Permissive
|
Mus musculus |
GSE24178
...
|
MA0654.1
|
ISX |
embryonic stem cells |
Treatment: 10 hrs doxycyline treatment; Strain: C57BL/6; |
Permissive
|
Mus musculus |
GSE65192
...
|
MA0654.1
|